Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Sacituzumab govitecan-hziy |
| Synonyms | |
| Therapy Description |
Sacituzumab govitecan is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sacituzumab govitecan-hziy | Trodelvy | IMMU-132|Sactizumab | Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more priotr therapies (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | triple-receptor negative breast cancer | not applicable | Sacituzumab govitecan-hziy | Case Reports/Case Series | Actionable | In a Phase I/II trial (IMMU-132-01), Trodelvy (sacituzumab govitecan-hziy) treatment resulted in a partial response in a patient with triple-negative breast cancer (PMID: 25944802; NCT01631552). | 25944802 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | Sacituzumab govitecan-hziy | FDA approved | Actionable | In a Phase I/II trial (IMMU-132-01) that supported FDA approval, Trodelvy (sacituzumab govitecan-hziy) treatment resulted in an objective response rate of 33.3% (36/108, 3 complete response, 33 partial response) and a clinical benefit rate of 45.4% in patients with metastatic triple-negative breast cancer who received two or more prior therapies, with a median duration of response, progression-free survival, and overall survival of 7.7, 5.5, and 13.0 months respectively (PMID: 30786188; NCT01631552). | 30786188 detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | Sacituzumab govitecan-hziy | Phase Ib/II | Actionable | In a Phase I/II trial (IMMU-132-01), Trodelvy (sacituzumab govitecan-hziy) demonstrated safety and preliminary efficacy, resulted in a partial response in 8% (2/25) and stable disease in 64% (16/25) of patients with advanced solid tumors, with a time-to-progression of 3.6 months (PMID: 25944802; NCT01631552). | 25944802 |
| Unknown unknown | lung small cell carcinoma | not applicable | Sacituzumab govitecan-hziy | Phase Ib/II | Actionable | In a Phase I/II trial (IMMU-132-01), Trodelvy (sacituzumab govitecan-hziy) treatment demonstrated safety, resulted in an objective response rate of 14% (7/50, 7 partial response) in patients with metastatic small cell lung cancer, Tacstd2 (Trop-2) expression was detected in 92% (23/25) of assessable tumor tissues, although expression level did not correlate with progression-free survival or overall survival (PMID: 28679770; NCT01631552). | 28679770 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02574455 | Phase III | Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) | Completed | USA | CAN | 5 |
| NCT03725761 | Phase II | Sacituzumab govitecan-hziy | IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | Suspended | USA | 0 |
| NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02) | Recruiting | USA | CAN | 7 |
| NCT03547973 | Phase II | Sacituzumab govitecan-hziy | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer | Recruiting | USA | 1 |
| NCT04448886 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Recruiting | USA | 0 |
| NCT04251416 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Suspended | USA | 0 |
| NCT04527991 | Phase III | Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) | Recruiting | USA | 1 |
| NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
| NCT03995706 | Phase I | Sacituzumab govitecan-hziy | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | Recruiting | USA | 0 |
| NCT04230109 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan In TNBC (NeoSTAR) | Recruiting | USA | 0 |
CKB BOOST